98%
921
2 minutes
20
Ketamine abuse has dramatically increased in recently years. With the widely application of ketamine, its side effects, especially cystitis induced by long-term use, have attracted more and more attention from the public. In the present study, we aimed to explore the potential generative mechanism of ketamine-induced cystitis by determining the endogenous metabolites at different time points after ketamine treatment. Body weight, bladder/body coefficient, urinary frequency, urinary potassium, serum IL-6, and TNF-α were determined at different time points after ketamine treatment. H&E staining was used to observe the changes of histopathology. Metabonomics was performed to determine the changes of endogenous metabolites. After 12 weeks of treatment, obvious inflammatory reaction was noticed in the KET group; the body weight and urinary potassium of the KET group were significantly lower than the NS group (P < 0.05) and other factors, such as urinary frequency, bladder/body coefficient, serum TNF-α and IL-6 were higher than the NS group (P < 0.05). A total of 30, 28, and 32 significantly changed metabolites were identified at the 1st week, 4th week and 12th week, respectively. Metabolic pathway analysis showed that different metabolic pathways were affected during the treatment process. Linoleic acid metabolism, beta-alanine metabolism, glyoxylate and dicarboxylate metabolism were only affected following long-term administration of ketamine. Those metabolic pathways may have a close relationship with cystitis induced by ketamine.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958055 | PMC |
Addiction
August 2025
Queen Elizabeth Hospital Birmingham - Urology, Birmingham, UK.
Ketamine-induced cystitis is an increasingly recognized complication associated with the addictive use of ketamine, a dissociative anesthetic. This article provides a comprehensive overview, focusing on its pathophysiology, clinical presentation, diagnosis, management strategies, and implications for addiction treatment. The British Association of Urological Surgeons consensus serves as a foundational reference for management, while additional literature is integrated to highlight the multifaceted nature of Ketamine Bladder and its impact on individuals with substance use disorders.
View Article and Find Full Text PDFHistopathology
July 2025
Institute of Liver Studies, King's College Hospital, London, UK.
Aims: To reveal clinical, imaging and pathological features of ketamine cholangiopathy.
Methods And Results: Eight cases, who had a history of long-term ketamine use, abnormal liver function tests and histological or radiological evidence of cholangiopathy, were retrospectively reviewed. Cases consisted of six men and two women with a median age of 36 years.
Inflamm Res
January 2025
Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Background: Mitochondrial dysfunction and damage can result in the release of mitochondrial DNA (mtDNA) into the cytoplasm, which subsequently activates the cGAS-STING pathway, promoting the onset of inflammatory diseases. Various factors, such as oxidative stress, viral infection, and drug toxicity, have been identified as inducers of mitochondrial damage. This study aims to investigate the role of mtDNA as a critical inflammatory mediator in the pathogenesis of ketamine (KET)-induced cystitis (KC) through the cGAS-STING pathway.
View Article and Find Full Text PDFCureus
October 2024
Nephrology, Middletown Medical, Middletown, USA.
Ketamine-induced uropathy (KIU) is a serious consequence of chronic ketamine abuse, presenting with complex renal and urinary symptoms. This study describes a 34-year-old female with a history of chronic ketamine abuse, resulting in stage 3 chronic kidney disease (CKD) and severe urological complications. Despite discontinuing ketamine use five years ago, she remains dependent on ureteral stents due to recurrent hydronephrosis and ureteral obstruction.
View Article and Find Full Text PDFFr J Urol
November 2024
Department of Urology, Rennes University Hospital, Rennes, France.
Objective: The objective of the CUROPF and CTMH was to establish recommendations about ketamine induced uropathy management.
Methods: A systematic review of the literature was conducted on Pubmed/Medline by the members of the French committees of female urology and male lower urinary tract symptoms focusing on the epidemiology, pathophysiology, diagnosis and treatment of ketamine induced uropathy, evaluating references and level of evidence.
Results: Recommendations include epidemiology, pathophysiology, diagnosis and treatment of ketamine induced uropathy.